Table 4 Characteristics of the ten patients who lived more than 1 year after brain recurrence
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
OSrec, mo. | 45.8 | 13.2 | 13.6 | 12.1 | 57.8 | 15.6 | 15.1 | 12.8 | 24.7 | 41.5 |
Age at brain recurrence, years | 62 | 61 | 71 | 63 | 57 | 64 | 69 | 63 | 64 | 65 |
ECOG PS score at brain recurrence | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
Sex | Male | Female | Female | Female | Female | Female | Female | Male | Male | Female |
Initial disease stage (limited or extensive) | Extensive | Extensive | Extensive | Extensive | Extensive | Extensive | Extensive | Extensive | Limited | Limited |
Extrathoracic organs involved at initial diagnosis | Brain, adrenal | Bone | Liver | Thyroid | Brain | Brain | Brain | None a | None | None |
No. of brain lesions at brain recurrence (1, 2–4 or ≥ 5) | 1 | 2–4 | 2–4 | 2–4 | ≥5 | 1 | ≥5 | 1 | 1 | 1 |
Symptoms from brain lesions at brain recurrence (no or yes) | No | No | No | No | No | No | No | No | No | Yes |
Extracranial disease at brain recurrence | Controlled | Uncontrolled | Controlled | Controlled | Controlled | Controlled | Controlled | Controlled | Controlled | Uncontrolled |
Time from the end of first brain irradiation to brain recurrence, mo. | 8.3 | 11.3 | 2.5 | 4.6 | 13.4 | 16.2 | 7.5 | 5.1 | 8.9 | 5.1 |
Treatment received for brain lesion after brain recurrence | SRS | SRS | SRS | SRS | Temozolo-mide | SRS (after surgery) | Temozolo-mide | SRS | SRS | SRS |
Chemotherapy after brain recurrence (no or yes) | Yes | Yes | Yes | No | Yes | No | Yes | No | No | Yes |
Additional brain failure after initial brain recurrence after WBI (no or yes) | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
Salvage therapy for additional brain failure after initial brain recurrence after WBI | Chemo | – | Chemo | SRS, repeat WBI afterwards | SRS | SRS | SRS | Observation | Observation | – |